What B-Symptoms Are in Lymphoma Patients?

a woman sick in bed looking at a thermometer

PM Images / Iconica / Getty Images

B symptoms may also be described as “systemic systems” or “general symptoms,” but in the case of lymphoma, the term refers to a specific set of three symptoms that may predict how the malignancy is likely to behave:

  • Fever (i.e., temperature >38C [>100.4F]) for 3 consecutive days
  • Weight loss without trying, exceeding 10% of body weight in 6 months
  • Drenching night sweats

A person with lymphoma and any one of the three symptoms above is said to have B symptoms. There are two major categories of lymphoma: Hodgkin lymphoma (HL) and non-Hodgkin Lymphoma (NHL). Patients with either type of lymphoma may develop B symptoms. One of the most common symptoms of lymphoma, in general, is the enlargement of lymph nodes.

B symptoms may or may not be present in various cases of lymphoma but when they are, they may help predict how the lymphoma will behave and which treatments might be best to start with. B symptoms are most common in more rapidly growing lymphomas.

B Symptoms and Their Significance

In some cases, the presence of B symptoms may also indicate that the disease may be present in parts of the body other than where it had been initially detected. The presence or absence of B symptoms at the time of diagnosis may be incorporated into the description of a person's disease.

When the doctor determines the stage of the disease and the individual has B symptoms, he or she adds the letter B after the stage (which may be between I to IV). So if someone is stage II with B symptoms, the stage is noted as II-B. The stages of those who don't have any of the B symptoms are noted as A.

There are many different types of lymphoma, and different lymphoma types can impact patients very differently. In the same way, the presence of B symptoms can be very important in some cases of lymphoma, but less so in other lymphoma types.

B Symptoms Associated With Transformation

Two of the most common types of NHL are follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBL). Follicular lymphoma is considered an indolent or slow-growing lymphoma, meaning it can “smolder” for many years before breaking out into a more aggressive, rapidly growing disease. When FL changes from smoldering to aggressive, this is referred to as transformation.

FL can transform into DLBCL, a more aggressive and rapidly growing lymphoma. Sometimes, an individual with FL never knew he or she had lymphoma and only comes to medical attention once the malignancy has transformed. One of the things that might lead a person to seek medical attention is the presence of B symptoms.

One group of researchers in 2015 looked at factors associated with the transformation of FL among 2,652 patients. After watching them for roughly 6-7 years, about 14 percent of them transformed following the initial FL diagnosis, including 147 biopsy-confirmed and 232 clinically suspected cases. They determined that lymphoma involvement outside of the lymph nodes, the elevation of a blood marker called lactate dehydrogenase, and B symptoms at diagnosis were associated with transformation risk.

3 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBOBMC Cancer. 2009;9(1). doi:10.1186/1471-2407-9-153

  2. Davies AJ, Rosenwald A, Wright G. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanismsBr J Haematol. 2007;136(2):286–293. doi:10.1111/j.1365-2141.2006.06439.x

  3. Wagner-Johnston ND, Link BK, Byrtek M. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Blood. 2015;126(7):851-857. doi:10.1182/blood-2015-01-621375

Additional Reading
  • Diagnostic and Therapeutic Advances in Hematologic Malignancies, edited by Martin S. Tallman, Leo I. Gordon.

  • Hematologic Malignancies. Demos Medical Publishing, Dec 17, 2012

By Indranil Mallick, MD
 Indranil Mallick, MD, DNB, is a radiation oncologist with a special interest in lymphoma.